Phoenix Bio

研究発表

研究発表

Acute HBV infection in humanized chimeric mice has multiphasic viral kinetics

    Ishida, Y. Chung, T. L. Imamura, M. Hiraga, N. Sen, S. Yokomichi, H. Tateno, C. Canini, L. Perelson, A. S. Uprichard, S. L. Dahari, H. Chayama, K.

    Hepatology. 2018 Mar 23. doi: 10.1002/hep.29891.

    Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection

      Rolt, A. Le, D. Hu, Z. Wang, A. Q. Shah, P. Singleton, M. Hughes, E. Dulcey, A. E.He, S. Imamura, M. Uchida, T. Chayama, K. Xu, X. Marugan, J. J. Liang, T. J.

      J Infect Dis. 2018 Jan 24. pii: 4823490. doi: 10.1093/infdis/jiy039.

      A natural small molecule inhibitor corilagin blocks HCV replication and modulates oxidative stress to reduce liver damage

        Reddy, B. U. Mullick, R. Kumar, A. Sharma, G. Bag, P. Roy, C. L. Sudha, G. Tandon, H. Dave, P. Shukla, A. Srinivasan, P. Nandhitha, M.Srinivasan, N. Das, S.

        Antiviral Res. 2017 Dec 7;150:47-59.

        Hepatitis C replication inhibitors that target the viral NS4B protein

          Miller, J. F. Chong, P. Y. Shotwell, J. B. Catalano, J. G. Tai, V. W. Fang, J. Banka, A. L. Roberts, C. D. Youngman, M. Zhang, H. Xiong, Z. Mathis, A. Pouliot, J. J. Hamatake, R. K. Price, D. J. Seal, J. W., 3rd Stroup, L. L. Creech, K. L. Carballo, L. H. Todd, D. Spaltenstein, A. Furst, S. Hong, Z. Peat, A. J.

          J Med Chem. 2014 Mar 13;57(5):2107-20

          Significance of aldehyde oxidase during drug development: Effects on drug metabolism, pharmacokinetics, toxicity, and efficacy

            Sanoh, S. Tayama, Y. Sugihara, K. Kitamura, S. Ohta, S.

            Drug Metab Pharmacokinet. 2015 Feb;30(1):52-63.

            A Novel Orally Available Small Molecule That Inhibits Hepatitis B Virus Expression

              Mueller, H. Wildum, S. Luangsay, S. Walther, J. Lopez, A. Tropberger, P. Ottaviani, G. Lu, W. John Parrott, N. Zhang, J. D. Schmucki, R. Racek, T. Hoflack, J. C. Kueng, E. Point, F. Zhou, X. Steiner, G. Lutgehetmann, M. Rapp, G. Volz, T. Dandri, M. Yang, S. Young, J. A. T. Javanbakht, H.

              J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32393-0. doi: 10.1016/j.jhep.2017.10.014.

              Efficacy of NVR 3-778, Alone and in Combination With Pegylated Interferon, vs Entecavir in uPA/SCID Mice With Humanized Livers and HBV Infection

                Klumpp, K. Shimada, T. Allweiss, L. Volz, T. Lutgehetmann, M. Hartman, G. Flores, O. A. Lam, A. M. Dandri, M.

                Gastroenterology. 2017 Oct 24. pii: S0016-5085(17)36276-5. doi: 10.1053/j.gastro.2017.10.017.

                Candidate genes responsible for early key events of phenobarbital-promoted mouse hepatocellular tumorigenesis based on differentiation of regulating genes between wild type mice and humanized chimeric mice

                  Ohara A , Takahashi Y,  Kondo  M,  Okuda Y, Takeda  S,  Kushida M, Kobayashi  K,  Sumida K, Yamada T

                  Toxicol Res. 2017; 6(6): 795-813

                  Evaluation of the human relevance of the constitutive androstane receptor-mediated mode of action for rat hepatocellular tumor formation by the synthetic pyrethroid momfluorothrin

                    Okuda, Y. Kushida, M. Kikumoto, H. Nakamura, Y. Higuchi, H. Kawamura, S. Cohen, S. M. Lake, B. G.Yamada, T.

                    J Toxicol Sci. 2017;42(6):773-788. doi: 10.2131/jts.42.773.

                    Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus

                      Sato, Y. Matsui, H. Yamamoto, N. Sato, R. Munakata, T. Kohara, M. Harashima, H.

                      J Control Release. 2017 Oct 3;266:216-225. doi: 10.1016/j.jconrel.2017.09.044.

                      Organic anion transporting polypeptides (OATPs)-mediated drug-drug interaction study between rosuvastatin and cyclosporine A in chimeric mice with humanized liver

                        Uchida, M. Tajima, Y. Kakuni, M. Kageyama, Y. Okada, T. Sakudara, E. Tateno, C. Hayashi, R.

                        Drug Metab Dispos. 2017 Oct 19. pii: dmd.117.075994. doi: 10.1124/dmd.117.075994.

                        Assessment of amiodarone-induced phospholipidosis in chimeric mice with a humanized liver

                          Sanoh, S. Yamachika, Y. Tamura, Y. Kotake, Y. Yoshizane, Y. Ishida, Y. Tateno, C. Ohta, S.

                          J Toxicol Sci. 2017;42(5):589-596. doi: 10.2131/jts.42.589.

                          Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus

                            Hamana, A. Takahashi, Y. Uchida, T. Nishikawa, M. Imamura, M. Chayama, K. Takakura, Y.

                            Antiviral Res. 2017 Aug 31;146:130-138.

                            Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages

                              Cheng, X. Xia, Y. Serti, E. Block, P. D. Chung, M. Chayama, K. Rehermann, B. Liang, T. J.

                              Hepatology. 2017 Jun 30. doi: 10.1002/hep.29348.

                              Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus

                                Tsuge, M. Uchida, T. Hiraga, N. Kan, H. Makokha, G. N. Abe-Chayama, H. Miki, D. Imamura, M. Ochi, H. Hayes, C. N. Shimozono, R. Iwamura, T.Narumi, H. Suzuki, T  Kainoh, M. Taniguchi, T.

                                Antimicrob Agents Chemother. 2017 May 24;61(6).

                                Critical role of CREBH-mediated induction of TGF-beta2 by HCV infection in fibrogenic responses in hepatic stellate cells

                                  Chida, T. Ito, M. Nakashima, K. Kanegae, Y. Aoshima, T. Takabayashi, S. Kawata, K. Nakagawa, Y. Yamamoto, M. Shimano, H. Matsuura, T. Kobayashi, Y. Suda, T. Suzuki, T.

                                  Hepatology. 2017 Jun 16. doi: 10.1002/hep.29319.

                                  The Smc5/6 Complex Restricts HBV when Localized to ND10 without Inducing an Innate Immune Response and Is Counteracted by the HBV X Protein Shortly after Infection

                                    Niu, C. Livingston, C. M. Li, L. Beran, R. K. Daffis, S. Ramakrishnan, D. Burdette, D. Peiser, L. Salas, E. Ramos, H. Yu, M. Cheng, G. Strubin, M. Delaney Iv, W. E. Fletcher, S. P.

                                    PLoS One. 2017 Jan 17;12(1):e0169648.

                                    Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor

                                      Decorsiere, A. Mueller, H. van Breugel, P. C. Abdul, F. Gerossier, L. Beran, R. K. Livingston, C. M. Niu, C. Fletcher, S. P. Hantz, O. Strubin, M.

                                      Nature. 2016 Mar 17;531(7594):386-9. doi: 10.1038/nature17170.

                                      Persistent Loss of HBV Markers in Serum without Cellular Immunity by Combination of PEG-IFN Plus ETV Therapy in Humanized Mice

                                        Uchida, T. Imamura, M. Hayes, C. N. Hiraga, N. Kan, H. Tsuge, M. Abe-Chayama, H. Zhang, Y. Makokha, G. N. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

                                        Antimicrob Agents Chemother. 2017 Jul 10. pii: AAC.00725-17. doi: 10.1128/AAC.00725-17

                                        Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)

                                          Wasiak, S. Gilham, D. Tsujikawa, L. M. Halliday, C. Calosing, C. Jahagirdar, R. Johansson, J. Sweeney, M. Wong, N. C. Kulikowski, E.

                                          J Cardiovasc Transl Res. 2017 May 31. doi: 10.1007/s12265-017-9755-z.